Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome.
Nijs, Jo, De Meirleir, Kenny · In vivo (Athens, Greece) · 2005
Quick Summary
This study looks at a specific immune system pathway called the 2-5A synthetase/RNase L pathway that may be broken in ME/CFS patients. Researchers found that in ME/CFS, this pathway is overactive but also working improperly—it's being broken down into unusual pieces instead of functioning normally. This abnormal pathway appears connected to reduced natural killer cell function and problems with how cells die when they should.
Why It Matters
Understanding the 2-5A synthetase/RNase L pathway dysfunction may explain key ME/CFS features including immune dysregulation and exercise intolerance. If this pathway is central to ME/CFS pathophysiology, it could become a target for new treatments and a biomarker for diagnosis.
Observed Findings
2-5A synthetase and RNase L activity are elevated in CFS patients
RNase L is abnormally cleaved into 37 and 30 kDa fragments via elastase and calpain
Pathway impairments correlate with reduced natural killer cell function
Dysregulation of apoptotic pathways accompanies pathway abnormalities
Components of the pathway relate to exercise stress test performance
Inferred Conclusions
The 2-5A synthetase/RNase L pathway is both upregulated and deregulated in CFS patients
Pathway dysregulation is associated with immune dysfunction and abnormal cell death pathways
The impaired pathway may be clinically relevant to CFS symptomatology and exercise intolerance
Does correcting 2-5A synthetase/RNase L pathway dysregulation improve CFS symptoms and exercise tolerance?
What initiates the pathway dysregulation in ME/CFS, and why do some patients show more severe impairments than others?
What This Study Does Not Prove
This review does not prove that 2-5A synthetase/RNase L pathway dysregulation causes ME/CFS—it shows association and mechanistic plausibility but not causation. It does not establish whether correcting this pathway would reverse ME/CFS symptoms, nor does it confirm these findings apply to all ME/CFS patients or explain the primary trigger of the dysregulation.